GB0215509D0 - Marker genes - Google Patents

Marker genes

Info

Publication number
GB0215509D0
GB0215509D0 GBGB0215509.1A GB0215509A GB0215509D0 GB 0215509 D0 GB0215509 D0 GB 0215509D0 GB 0215509 A GB0215509 A GB 0215509A GB 0215509 D0 GB0215509 D0 GB 0215509D0
Authority
GB
United Kingdom
Prior art keywords
marker genes
genes
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0215509.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0215509.1A priority Critical patent/GB0215509D0/en
Publication of GB0215509D0 publication Critical patent/GB0215509D0/en
Priority to CA002493860A priority patent/CA2493860A1/en
Priority to PCT/EP2003/007111 priority patent/WO2004005544A2/en
Priority to AU2003250879A priority patent/AU2003250879B2/en
Priority to EP07119607A priority patent/EP1925677A3/en
Priority to EP03762612A priority patent/EP1521847A2/en
Priority to JP2004518691A priority patent/JP2005531321A/ja
Priority to CNA038187833A priority patent/CN1688715A/zh
Priority to BR0312405-3A priority patent/BR0312405A/pt
Priority to US10/518,575 priority patent/US20060008804A1/en
Priority to IL16588304A priority patent/IL165883A0/xx
Priority to JP2009233624A priority patent/JP2010042019A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0215509.1A 2002-07-04 2002-07-04 Marker genes Ceased GB0215509D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB0215509.1A GB0215509D0 (en) 2002-07-04 2002-07-04 Marker genes
US10/518,575 US20060008804A1 (en) 2002-07-04 2003-07-03 Marker genes
EP07119607A EP1925677A3 (en) 2002-07-04 2003-07-03 Marker genes for determining renal toxicity
PCT/EP2003/007111 WO2004005544A2 (en) 2002-07-04 2003-07-03 Marker genes for determining renal toxicity
AU2003250879A AU2003250879B2 (en) 2002-07-04 2003-07-03 Marker genes for determining renal toxicity
CA002493860A CA2493860A1 (en) 2002-07-04 2003-07-03 Marker genes for determining renal toxicity
EP03762612A EP1521847A2 (en) 2002-07-04 2003-07-03 Marker genes for determining renal toxicity
JP2004518691A JP2005531321A (ja) 2002-07-04 2003-07-03 マーカー遺伝子
CNA038187833A CN1688715A (zh) 2002-07-04 2003-07-03 用于确定肾中毒的标记基因
BR0312405-3A BR0312405A (pt) 2002-07-04 2003-07-03 Genes marcadores
IL16588304A IL165883A0 (en) 2002-07-04 2004-12-20 Marker genes for determining renal toxicity
JP2009233624A JP2010042019A (ja) 2002-07-04 2009-10-07 マーカー遺伝子

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0215509.1A GB0215509D0 (en) 2002-07-04 2002-07-04 Marker genes

Publications (1)

Publication Number Publication Date
GB0215509D0 true GB0215509D0 (en) 2002-08-14

Family

ID=9939850

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0215509.1A Ceased GB0215509D0 (en) 2002-07-04 2002-07-04 Marker genes

Country Status (10)

Country Link
US (1) US20060008804A1 (https=)
EP (2) EP1925677A3 (https=)
JP (2) JP2005531321A (https=)
CN (1) CN1688715A (https=)
AU (1) AU2003250879B2 (https=)
BR (1) BR0312405A (https=)
CA (1) CA2493860A1 (https=)
GB (1) GB0215509D0 (https=)
IL (1) IL165883A0 (https=)
WO (1) WO2004005544A2 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE425249T1 (de) 2000-06-16 2009-03-15 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
DK1401869T3 (da) 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
EP2025345A1 (en) 2002-12-30 2009-02-18 Biogen Idec MA Inc. KIM-1 antagonists and use to modulate immune system
CA2565701A1 (en) * 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
ES2818028T3 (es) * 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
KR101213894B1 (ko) 2005-03-02 2012-12-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｔｈ2 매개성 병태를 치료하기 위한 ｋｉｍ-1 항체
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008113363A1 (en) 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
CN103399155A (zh) * 2007-03-26 2013-11-20 诺瓦提斯公司 用于监测肾功能的预测性的肾安全性生物标志物和生物标志物标签
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
ES2475990T5 (es) * 2007-11-15 2017-07-06 Bioporto Diagnostics A/S Uso diagnóstico de formas moleculares individuales de un biomarcador
EP2075343A1 (en) * 2007-12-21 2009-07-01 Gert Mayer A method of diagnosing a progressive disease
EP2279270B1 (en) * 2008-04-15 2014-06-18 Oberbauer, Rainer Markers of acute kidney failure
US7977110B2 (en) 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
ES2341419B1 (es) * 2008-08-14 2011-05-03 Hospital Clinic I Provincial De Barcelona Wnt1 como biomarcador de daño renal.
JP2012508177A (ja) * 2008-11-05 2012-04-05 アボット・ラボラトリーズ 尿および組換えチャイニーズハムスター卵巣（ｃｈｏ）細胞から濃縮された好中球ゼラチナーゼ関連リポカリン（ｎｇａｌ）タンパク質アイソフォーム、ならびに関連する組成物、抗体、ならびに濃縮、分析および使用の方法
CN102264230B (zh) * 2008-11-10 2014-12-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
MX2011005379A (es) * 2008-11-22 2011-06-09 Astute Medical Inc Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
CN102301008B (zh) * 2009-01-19 2015-05-13 生物梅里埃公司 用于确定患者发生医院内感染的易感性以及确立败血性综合征进展的预后的方法
PT2391653E (pt) 2009-01-28 2015-02-13 Ind Tech Res Inst Biomarcadores associados a nefropatia
US20110065599A1 (en) * 2009-08-07 2011-03-17 Rules-Based Medicine, Inc. Methods and Devices for Detecting Kidney Damage
WO2011084791A2 (en) * 2009-12-21 2011-07-14 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
EP2517020B1 (en) 2009-12-23 2015-10-21 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP5804629B2 (ja) * 2011-07-29 2015-11-04 株式会社メディクローム 遺伝子発現変動解析による化学物質の毒性評価方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN106018783A (zh) * 2011-09-14 2016-10-12 巴斯夫欧洲公司 用于评估肾毒性的手段和方法
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
SI2912165T1 (sl) * 2012-10-24 2019-11-29 Inregen Populacije ledvičnih celic in njihova uporaba
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014182330A1 (en) 2013-05-06 2014-11-13 Hitachi Chemical Company Ltd Devices and methods for capturing target molecules
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015153860A1 (en) * 2014-04-04 2015-10-08 Somalogic, Inc. Glomerular filtration rate biomarkers and uses thereof
WO2015160805A1 (en) * 2014-04-15 2015-10-22 The Brigham And Women's Hospital, Inc. Circulating kim-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
EP3189164B1 (en) 2014-09-05 2021-11-10 American University Of Beirut Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger rna
EP3218521B1 (en) * 2014-11-12 2019-12-25 Hitachi Chemical Co., Ltd. Method for diagnosing organ injury
WO2016208776A1 (ja) 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
JP6432962B2 (ja) 2016-03-29 2018-12-05 株式会社国際電気通信基礎技術研究所 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
JP7012033B2 (ja) * 2016-06-17 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー インビトロ腎毒性スクリーニングアッセイ
EP3695224A4 (en) * 2017-10-12 2021-12-29 Cedars-Sinai Medical Center Prognosis and progression biomarkers for chronic kidney disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA951461B (en) * 1994-02-22 1996-01-24 Univ Illinois Genes and genetic elements associated with sensitivity to platimun-based drugs
US6586389B1 (en) * 1998-01-22 2003-07-01 Administrators Of The Tulane Educational Fund Cubilin protein, DNA sequences encoding cubilin and uses thereof
CA2340589A1 (en) * 1998-08-28 2000-03-09 Incyte Pharmaceuticals, Inc. Toxicological response markers
WO2000047761A2 (en) * 1999-02-12 2000-08-17 Phase-1 Molecular Toxicology, Inc. High-throughput toxicological testing using cultured organisms and cells
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
WO2001032928A2 (en) * 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
US20020037508A1 (en) * 2000-01-19 2002-03-28 Michele Cargill Human single nucleotide polymorphisms
ATE425249T1 (de) * 2000-06-16 2009-03-15 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
EP1356093A2 (en) * 2000-06-21 2003-10-29 Hitachi Chemical Co., Ltd. Gene markers for lung cancer
US20020142284A1 (en) * 2000-07-13 2002-10-03 Debasish Raha Methods of identifying renal protective factors
CA2395781C (en) * 2000-07-13 2010-04-13 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
CA2414421A1 (en) * 2000-07-31 2002-02-07 Gene Logic, Inc. Molecular toxicology modeling
DE10056802B4 (de) * 2000-11-14 2005-06-16 Epigenomics Ag Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
WO2002066682A2 (en) * 2001-01-29 2002-08-29 Phase-1 Molecular Toxicology, Inc. Rat toxicologically relevant genes and uses thereof

Also Published As

Publication number Publication date
IL165883A0 (en) 2006-01-15
BR0312405A (pt) 2005-04-26
JP2010042019A (ja) 2010-02-25
WO2004005544A3 (en) 2004-04-22
EP1925677A3 (en) 2008-07-02
US20060008804A1 (en) 2006-01-12
EP1925677A2 (en) 2008-05-28
AU2003250879A1 (en) 2004-01-23
AU2003250879B2 (en) 2007-07-26
EP1521847A2 (en) 2005-04-13
CN1688715A (zh) 2005-10-26
CA2493860A1 (en) 2004-01-15
WO2004005544A2 (en) 2004-01-15
JP2005531321A (ja) 2005-10-20

Similar Documents

Publication Publication Date Title
GB0215509D0 (en) Marker genes
AU2003277149A8 (en) Synthetic genes
AU2003218483A8 (en) Novel expressed genes
GB2402838B (en) Rate color marker
AU2003251905A8 (en) Synthetic tag genes
GB2394697B (en) Marker pens
GB0225360D0 (en) Genetic markers
GB0307643D0 (en) Markers
GB2406644B (en) Viral marker
GB0223982D0 (en) Marker gene
GB2403931B (en) Marker pens
AU2003294705A8 (en) Ntsm gene
GB0307640D0 (en) Markers
IL148158A0 (en) Marker for sign
AU2003219725A8 (en) Angiogenesis genes
EP1518929A4 (en) NEW GENES
GB0214381D0 (en) pHEJ1 Plasmid
GB0208499D0 (en) Streptococcal genes
IL149253A0 (en) Acrylic marker
GB0211365D0 (en) Marker pens
GB0222701D0 (en) Trainer
GB2402367B (en) Book marker
GB0312052D0 (en) Marker bouy
HK1074222A (en) Marker gene
GB0215188D0 (en) Height-related gene

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)